• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A novel anthracycline antibiotic complex designated herein as bohemic acid complex is produced by fermentation of Actinosporangium sp. A.T.C.C. 31127. The complex and two bioactive components designated marcellomycin and musettamycin exhibit antibiotic activity and inhibit the growth of various tumor systems in rodents.
    公开号:SU786914A3
    申请号:SU772469957
    申请日:1977-04-15
    公开日:1980-12-07
    发明作者:Е.Неттлтон Дональд (Младший)；А.Баш Джеймс；Т. Брэднер Уильям；Х. Шрайбер Ричард
    申请人:Бристоль-Мейерд Компани (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to the microbiological industry and concerns the production of antibiotics.
    The proposed antibiotics are new and the method for their preparation is not described in the patent and scientific literature.
    The aim of the invention is to obtain an antibiotic complex of the general formula:
    about him
    SNDS
    Nlchjlf
    V
    zT OL-r-J G he
    oh L
    where R is hydrogen (antibiotic mushetamycin)
    Nz
    ABOUT
    {antibiotic marcelG
    or
    he
    oil
    Lomitsin).
    10 This goal is achieved by the fact that
    strain Ac t i nosporang i urn sp. ATCC 31127 is grown under aerobic conditions in a nutrient medium containing sources of nitrogen and carbon, followed by dividing the complex from the culture fluid and releasing it into mustamicin and marcellomycin.
    In addition, the target product is isolated by extraction with organic rast2Q water immiscible scavenger.
    And the antibiotic complex is separated by gel filtration chromatography.
    Musetamicin and marcellomycin are additionally nytel. But they are purified by high pressure liquid chromatography.
    The strain Asprangiurn sp.ATCC 31127 was obtained from a soil sample taken in Ontario (Canada) and deposited in the American Type Culture Collection, Bamington DS The strain forms a spore ngia-like body (a false cnopaHr iftJ at the end of the book is an appendix of the mouth of a convoluted spore chain. Spores are intertwined with the air gifs. A sporangia-like body and aerial micelle. and agar with oat flour. Spores in bodies of sporangium type are smooth on the surface, ellipsoidal in shape and stationary. Primary mycelium is branched, not divided by partitions and does not form fragments. grows on most agar media. Cultural properties. Sugar nitrate agar. Growth is moderate, substrate mycelium is yellowish-red, aerial mycelium is poor, whitish, pigment is absent. Glucose-aspartic agar. Growth is good, substrate mycelium from red-orange to red, aerial mycelium abundant with grayish foliage, pigment absent or reddish orange. Glycerin-aspartic agar. Grown good, substrate mycelium pink aerial mycelium moderate light gray to pale pink, pigment no or reddish pink. Starch agar with inorganic salts. Growth is moderate, substrate mycelium is reddish-orange to bright red, aerial mycelium is bad, greenish foliage, pigment is light orange, partly light yellow Tyrosine agar. Growth is good, substrate mycelium is brown to reddish-brown, substrate mycelium is greenish, foliage, pigment dark brown Agar with malt yeast extract. Growth good, substrate mycelium bright red (aerial mycelium moderate, color aerovatoy foliage partially greenish pink pigment light brown. Agar with oat flour. Growth moderate substrate mycelium rky reddish orange aerial mycelium colored grayish foliage pigment bright orange Physiological properties. Optimal growth at 28 C. Moderate growth at 20-37 ° C. Slow growth at, does not grow at 10 ° C. Restores nitrates, on the milk-removing agar forms mycelial pigment from bright yellowish red to purple 10% solution of clear milk does not peptonize and does not coagulate, okrakra sews in a reddish-orange color. Gelatin dilutes, melanin forms. It absorbs arabinose, O-xylose, ribose, L-ramnose, D-glucose, O - galactose, fructose, mannose, sucrose, maltose, lactose, melabiose, raffinose, soluble starch, glycerin, inositol, mannitol. Does not absorb 0-arabinose, malesitose, cellulose, sorbitol, fulcit. ATCC 31127 under aerobic conditions in an aqueous nutrient medium containing -supused carbon sources, for example sucrose, lactose, maltose, mannose, fructose, glucose, glycerin and soluble starch. As an assimilable source of nitrogen, for example, fish meal, peptone, soybean flour, peanut powder, cotton seed powder or corn extract are used. Inorganic salts such as salts of sodium, potassium, ammonium, calcium, phosphate, sulfate, chloride, bromide, nitrate, and carbonate are also added to the medium. The cultivation is carried out with the following (Peratura 20-37-C, preferably at a temperature of 270c. The medium must be slightly alkaline. Fermentation is carried out in Erlenmeyer flasks or fermentors of different capacity. Seeding material in nutrient broth is obtained by inoculation of a small volume of culture The medium is transferred under aseptic conditions into a tank with an enzymatic medium. Sterile air is blown into the culture medium. The preparation of the antibiotic complex is achieved after incubation for e 190-210 hours in agitated fermenters. The course of fermentation is monitored by analyzing the enzymatic environment on the effects of an organism sensitive to the complex, such as D. pneum oniac, St.pyogefies or S.aureus. The antibiotic complex is extracted from the fermentative medium by extraction which is not miscible with water with an organic solvent, such as ethyl acetate, methyl isobutyl ketone or n-butanol at pH 7.5-8.5. The organic phase is then filtered and dried to obtain a solid complex. The antibiotics mussettamycin and marcellomycin are separated from each other and other components of the complex by chromatography on a column filled with Sephadex LH-20. The components of the complex are then eluted from the adsorbent with a suitable organic solvent, such as chloroform. Multiple fractions are collected at half-dilution. their adsorption capacity at 490 nm is determined. The resulting values are plotted against the fraction numbers to determine the peaks for the components eluted from the column. Suitable. fractions are combined and evaporated to separate solid antibiotics.
    Investigated organism
    Bacteria
    Streptococcus pnemoniae
    Streptococcus pyogenus
    Staphy1ococcus aureus
    Staphy1ococcus aureus
    Escherichia coli
    Escherichia coli
    Rlebsiella pneumoniae
    Proteus mirabilis Fungi
    The minimum inhibitory concentrations, lg / mm. The components of mustamicin and marcellomycin are further purified using high pressure liquid chromatography, in Table. Figure 1 shows the antimicrobial spectrum of mustamicin and marcellomycin. Table 1
    The LDgQ, which is acutely poisoned when given intraperitoneally to mice, is 9.8-21.12 microns / kg of mustamicin and 6.35-10.56 mg / kg for marcellomycin. Treatment of animals with an enzymatic broth containing the antibiotic complex causes 73% inhibition. tumor growth compared to untreated control tumors. The antibiotic complex and its components mussetamycin and marcellomycin, their salts and mixtures have both antimicrobial and antitumor effects. Preparations can be in any dosage form — tablets, capsules, pills, powders, and granules, as well as liquid preparations for oral administration such as solutions, suspensions, syrups, and elixirs. For use as an antibacterial agent, the drugs are administered in such a way that the concentration of the active ingredient exceeds the minimum inhibitory concentration. The dosage for use as an antitumor agent for a mammal is 2.5-10 mg / m in a single injection for marcellomycin and 10-40 mg / m in a single injection for mustamicin. The method is illustrated by the following examples. Example 1. The strain of the microorganism Actinosporangiurn sp. (ATCC 31127) is grown on oblique agar medium containing 2 g of B -glucose, 20 g of oatmeal, 2 g of soy peptone and 2 g of agar in one liter of distilled water. After incubation for at least 6 days at. 27 ° C spores are transferred to a 500 ml Erlenmeyer flask containing 100 ml of sterile medium containing 30 g of D-glucose, 10 g of soy flour, 10 g of Pharmamedia and 3 g of CaCOj per liter of distilled water. Received hyi :; The thermostat is kept in a thermostat at 2.1-C in a multi-colored stirring mixer, with a pressure of 210 rev / min. After 48 hours, 4 ml cultures were transferred to an Erleimemeer flask with a capacity of 500 ML containing 100 ml of sterile production medium containing 50 g of glycerol, 20 g of soy flour, 10 g of peanut powder and 10 g of CaCQj per liter of distilled water. The culture was excreted in a thermostat for 144 hours, placed in a shaking apparatus, producing 230 rpm. At this point, the antibiotic activity of the culture and filtrate determined by the antibiotic acid complex is determined.
    Example 2. An antibiotic complex is prepared in agitators with agitation using the 48 hour culture described in example 1. 400 ml of the culture is transferred to 10 liters of sterile production medium described in example 1 containing 0.01% Kodak P1 silicone antifoam contained in a 14 l shaker. The shaker is installed in the fermenter system. Maintain the temperature, air flow rate (i l / min, stirring speed 300 06./min. Hodag P1 anti-foaming agent is fed automatically as needed to control foaming. Approximately after 210 h the incubation is completed, and antibiotic is found in the culture medium and mycelium complex. Example 3. A fermenter tank with 37.8 l of sterile production medium (as in Example 1) is inoculated with 1.89 l of vegetative culture (obtained according to the method of Example 1} and the mixture is mixed using a propeller agitator, which makes 300 revolutionsMinute ,. aeration is carried out at a rate of 85 l / min, and the mixture was incubated at for 190 hours. The culture mycelia filtrate.i Nachod m antibiotic complex.
    Example 4. A tank-fermenter with a 3028 l producing medium (see example 1) is inoculated with 152 l of a vegetative culture (for preparation, see example 1 mixed by a propeller agitator making 155 rpm aerated at an air supply rate of 141.6 l / min and kept for 190 hours. At this point, the presence of the complex is detected in the culture filtrate and mycelium.
    Example 5. The whole fermentation broth (7 l) with a pH value of 8.1 is mixed with an equal volume of methyl isobutyl ketone for 20-30 minutes. Then a large amount of diatomaceous earth is added as a filter medium and, after thoroughly mixing the mixture, it is filtered through filter aid during vacuum. The filtrate is divided into two phases, of which the lower one (the aqueous is discarded. The organic phase is evaporated under vacuum to a small volume (50-100 ml), diluted with Skellisolve B and a bright red color is precipitated, which is dried under vacuum to give 1, 9 g complex.
    Example 6. The whole enzymatic broth (8000 l) at pri 8.0-8.5 is cooled to and vigorously mixed with 3000 l of methyl isobutyl ketone for 30 minutes at 20-ZOOs. 360 kg of filtering agent is added to the emulsion and the mixture is stirred vigorously for one more hour. The mixture is then allowed to settle for about 30 minutes, after which 23002500 l of the organic phase is decanted and cooled to. Another 800 l of methyl isobutyl ketone is added while the mixture is stirred for 20 minutes, decanted after settling for 30 minutes and the mixture is combined with the cooled first fraction to give a total extract volume of 33003400 l. The mixture is filtered to obtain i, B ultimately, 3100-3200 l of methyl isobutyl ketone extract, not containing solid particles and insoluble aqueous phase. The organic extract is concentrated under vacuum at 0–2 to a final volume of 6 l. The resulting concentrate is added to 60 L of Skellisolva B with stirring at 20-25 ° C. The precipitated precipitate is collected on a suction filter, washed with 10 l of Skellisolva B and sucked off to obtain 900-1000 g of a somewhat oily and dark red amorphous product. The resulting product is stirred with an excess of ether, filtered through a Buchner funnel, washed with additional ether, sucked off and dried under vacuum to obtain 351 g of an amorphous red antibiotic complex.
    Example 7. Sephadex LH-20 impregnated with chloroform for 68 hours is placed in a column filled with Pharmaceutical Product SK 25/100 (internal diameter 25 mm, height 100 TvUvi), equipped with adjustable Teflon nozzles at each end. Colon-yu is filled in such a way that it is completely filled from one end to the other to form an effective layer with a height of 90-95 cm. The bohemian acid complex (500 mg) is dissolved in 10 ml of chloroform and introduced into a column, which is then is chloroform, skipping 1 g; 1 m of warm-down to the bottom with a speed of 1 ml / min. .1 activated fluid is collected in 6 ml fractions in a fraction collector. Samples placed in numbered tubes were diluted with an 80-fold amount of chloroform and placed in a Bosch calorimeter at 490 MJU. The following four bands of anthracycline pigment are noted: P test tubes Weight after evaporation 1-4 5-11 First strip 66 mg 12-14 15-21 Second strip 36 mg 22-35 36-44 Third strip 18 mg 4546-57 Quarter strip 48 mg 58 Received solids are chromatographed on Brinkman silica gel on 607254 placed on plates for thin layer chromatography using a solvent system containing toluene and methanol (80:20). The first band, as shown by thin layer chromatography, reflects the complex inactive mixture. The second lane gives the characteristic orange-red zone with an R value of 0.75. This fraction is also inactive, and, as was found, it contains mainly pyrromycinone. The third elution fraction forms a single zone with an Rj value of about 0.3. This fraction was found to correspond to .musetamycin, which is highly active when tested on leukemia systems L-121 and P-388 in mice. The last band gives an area with a R value of about 0.3 and contains predominantly marcellomycin. This component also has high activity when tested on two types of leukemias in mice. Hot as musrutamycin and marcelfraction Description
    0
    1st component mixture, inactive 6,74 44
    2nd component, mixture, inactive 53 cavity - drop 70
    3rd component, one compound mustamicin, active
    75
    hollow - drop 110
    4th component, a mixture containing predominantly marcellomycin, active
    -2.00 subsequent fractions
    shown by thin layer chromatography
    XX predominantly p-pyrimicinone.
    Xx
    4.18
    0.385
    1.45 0.198
    4.03 1.72 Lomitsin, with thin layer}) chromatography, gives a value of R, of about 0.3, and the mustamicin moves f slightly faster. When separating the mixture of mussettamycin and marcellomycin, two zones are formed that are very similar in color. Example 8. A glass column with a diameter of 15.2 cm and a height of 184 cm is provided at its base with an unforgettable filter, on top of which a layer of glass fiber is placed, and even higher a circular plate of polyethylene. The latter is cut to a diameter of 14.9 cm in order to swell in chloroform. Sephadex, 8.73 kg is stirred for 3 hours in chloroform; filtered and the solid material is layered again with chloroform, and then it is left to stand for 16 hours. The mixture is then stirred in a 15 -pp and loaded into a column. 30 i-sample of the complex (preparation of sample 6 example) was heated with 1.5 l of chloroform for 15 minutes and then stirred for 16 hours. After the filling, 7.5 g of undissolved material containing some active substance were separated. injected into the column and begin to show chloroform: - from top to bottom. During the whole operation, chloroform flow rate is maintained at 16 ml / min. Before color formation reaches the bottom layer of gel, the initial eluent volume is 1445 ml. l omeite collect fractions of 100 m l, and this operation is continued until a completely clear liquid is obtained (a total of 906 fractions). Equal 1 quantities of the fifth fraction are diluted and poured to the analysis, as described in npiiwepe 7, the Four components are capable of separation, as shown. T c 2 Weight after u pariviai, g
    Example 9 A solid of 421.4 mg, obtained from the third component of Example 8, was dissolved in an excess of boiling chloroform, and the solution was filtered while hot through a corrugated Zumaga filter. The filtrate is boiled to less than 20 ml in a steam bath. Skellisolve B is then added to the warm solution until it reaches a cloud point, after which a few drops of chloroform are added. After cooling to ambient temperature, the mixture is placed in a refrigerator at -20 ° C overnight. Collect the bright red crystal plates and dry under vacuum to obtain 358 mg of mustahamycin, mp. 162-1ЗЗ.
    Example 10. Mosetamicin, washed with ethylenediaminetetraacetic acid (EDTA), is passed through four column systems of jU-STIRAGEL using chloroform as the mobile phase with a flow rate of 0.7 ml / min at the beginning of the process. Nine experiments were performed using 100 g each. Elution was recorded using a refractive index detector and fractions were collected which gave a main peak (37.5-45 minutes). The axillary fraction, taken from nine experiments, was combined and evaporated to dryness under vacuum. An amorphous dark red solid of 660 mg is dissolved in 22 ml of a mixture of solvents (45:55) from acetonitrile and 0.01 M sodium acetate, pH 4.0. The mixture is centrifuged to remove a small amount of suspended material, and the transparent upper layer is transferred to a closed penicillin jar. A portion (1.25 ml, about 37 mg) of the dark red solution is loaded into the injector, and then the image is loaded onto the column. The sample is chromatographed on a stainless steel column of 1 m length and an internal diameter of 4.6 mm, filled with Phenyl / SIZE B (particle size 3775 microns). Mobile pha contains a mixture of acetonitrile and 0.01 M sodium acetate (35:65) with a pH of 4.0 (flow rate 1.9-2.0 ml / min). Elution is recorded using a refractive index recorder. Fractions are collected at intervals of 75 seconds using an automatic fraction collector. The fractions are collected in 120 tubes and the column is washed with a speed of 3.0 MJi / min with methanol for 15 minutes, water for 15 minutes, a mixture of acetonitrile and 0-, 01 M nari acetate (35:65) at pH 4 for The flow rate is reduced to 2.0 ml / mi and the system is neutralized for 5 minutes by re-injection. 25 μm of eluent is quantified by a fifth tube on an analytical system for
    Determine the composition before combining the tubes. The analytical system contains a 61 cm long stainless steel column with an internal diameter of .2.1 mm, filled with phenyl / CORESILE. (Consists of solid glass balls coated with one layer of silica, to which diphenyldichlorosilane is attached, particle size 37-50 um).
    The mobile phase is a mixture (45:55) of acetonitrile with 0.01 M sodium acetate with a pH of 4. O, at a flow rate of 0.7 ml / min. The eluent is recorded with a UV detector at 254 nm. A combination of test tubes is performed based on chromatogram analysis. Tubes 21-120 contain the target mussettamycin. The contents of these tubes are combined and evaporated under vacuum (45 ° C). Dark red residues are washed several times with methanol and twice with 100 ml of dichloromethane. The residue is then triturated with 100 ml of chloroform and filtered to remove inorganic salts. The solid is then evaporated to dryness with dry nitrogen and dried under vacuum with phosphoric anhydride.
    Musettamcin, purified according to the method described above, is characterized by the following data:
    Crystalline powder of dark red color.
    Molecular formula: Molecular weight: 715.76.
    Elementary analysis:
    Theoretically: C 60.41; H 6.34; N 1.95.
    Found: C, 60.27; H 6.59; Kl, 99.
    Taking into account the correction for the presence of 0.83 water and 0.83 residue:
    C 60.27; H 6.50, N 1.99.
    IR spectrum: The infrared absorption spectrum of mussettamycin (KBr granules) shows large bands at the following wavelengths: 3480, 2970, 2930, 2820, 2770, 1735, 1600, 1450, 1320, 1295, 1220, 1160, 1010, and 990 cm
    UV spectrum: At a concentration of 0.013 g / l in methanol, mussettamycin shows the following maximum absorption maxima: 233 MJU, 57.7, 256 mi, 33.2, 284 MJJ, 14.5, 466 MJJ, 14.3, 490 ppm (, 17.4, 510 mp, 14.6, 524 MJJ, 12.9 and 570 mM, 3.3.
    T. pl. 210-2120C.
    Soluble in most organic solvents, insoluble in water, aliphatic hydrocarbons and ether.
    权利要求:
    Claims (2)
    [1]
    Example 11. Untreated marcellomycin, washed with EDTA, was subjected to an initial purification using a system of four TIRAGEL columns using chloroform as the mobile phase. The flow rate for such a separation is 0.6-0.7 MP / min, and the elution is recorded with a refractive index detector. 10 passages of 100 mg each are performed, and in each case, a fraction is taken, the elution of which takes place in 26-32 minutes. The main fraction of 10 passes is combined and evaporated to dryness under vacuum. The amorphous dark red solid is divided into 25 fractions of 30-35 mg. Each fraction is dissolved in 1.0 ml of a mixture (45:55) of acetonitrile and 0.01 M sodium acetate (pH 4, O, immediately before being loaded into the xyrography system, which is a 1 m x 4.6 mm stainless steel column Filled with Phenyl / VOLATIL B (contains completely porous silica with a liquid phase of diphenyldichlorosilane, chemically bound to silica (particle size 37–75 µm). The mobile phase is a mixture (45:55) of acetonentril and 0.01 M acetate sodium, pH is 4.0; flow rate 3.0 ml / min. Elution is recorded using a monitor refractive index differences. Fractions are collected at intervals of 1, 0 minutes with the help of collector fraction M 1. Contents of 59 tubes are collected and the column is washed with a flow rate of 4.0 ml / min with acetonitrile and for 15 minutes with a mobile phase before injection. each fifth tube is chromatographed on an analytical system, after which the contents of the tubes are combined. The analytic system is a 61 cm long stainless steel column and an internal diameter of 2.1 mm filled with Phenyl / CORESIL (contains erdye glass beads coated with a single layer of silica, which is chemically coupled with diphenyldichlorosilane (particle size - 37-50 microns). The mobile phase contains a mixture (45:55) of acetonitrile with 0.01 M sodium acetate (pI 4.0}, a flow rate of 0.68-7.0 ml / min. Elution is recorded using a UV detector at 254 mmkm. In this The system is injected with 25 ml of eluite. The tubes are combined on the basis of analytical chromatograms. In general, it has been found that tubes 18-35 contain exclusively target marcellomycin. The contents of these tubes are combined and evaporated to dryness under vacuum. The residue is quickly washed with methanol and twice 100 ml of dichloromethane. The residue is triturated with 75 ml of dichlormeth a and the mixture is filtered. The filtrate is evaporated under vacuum (45 ° C) to dryness. The bright red residue is then dried under high vacuum over phosphoric anhydride. Marcellomycin after the above-described purification is characterized by the following data: Amorphous dark red and yellow powder. Molecular formula: C SS-IT Molecular weight: 845.90. Elementary analysis: Theoretically: C 59.64; H 6.55; N 1.65; about 32.15. Found: C 56.32; H 6.64; N1, 74. Water correction and residue: C 58.77; -N 6.77; N 1.82. IR spectrum: The infrared absorption spectrum of marcellomycin (KBr granules) shows large bands with the following wavelengths: 3450, 2960, 2940, 2820, 2790, 1730, 1615, 1600, 1450, 1260, 1095, 1010 and 800 cm. UV -spectrum: At a concentration of 0.013 g / l in methanol, marcellomycin shows the following maxima and adsorptive abilities: 233 Mf (, 47.5, 256 mm, plateau, 24.7; 284 M | J, plateau, 10.6; 490 m / x, 15.8; 410 MjL), plateau, 3.4; 4.65 Mju, Plateau, 13.2; 480 cubic meters, plateau, 14.7; 510 m | a, plateau, 12.5; 524 m | ts, plateau ,, 10,6; 580 MjD, Plateau 1.1. Melting point: softening at 134-135 ° C, gradual thickening without melting at temperatures up to 300 ° C. The proposed method allows to obtain an antibiotic complex containing antibiotics marcellomycin and mussettamycin, which have an antitumor effect. Claim 1. Invention method for producing an antibiotic complex of the general formula COOSE O OH P OH O OH CHZ n I K (CH3) 2 J U-r-g it is where R is hydrogen (antibiotic mussettamycin) (antibiotic marcelllomycin,
    157869141.6
    characterized in that the solvent is immiscible
    strain Actinosporang urn sp. ATCC 31127 with water.
    grown under aerobic conditions in pi-3, the method according to claim 1, characterized by the environment, with, the source and the fact that the antibiotic
    Nitrogen and carbon followed by "7lex." is separated by gel from the culture liquid with a composite filtration chromatography, plex and its separation into matsin 4. The method according to claim 1, characterized by the fact that marcellomicin and
    [2]
    2. The method according to Claim 1;
    y u and with the fact that the target is pro-using liquid chromatography
    The product is isolated by extraction with high pressure.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU786914A3|1980-12-07|Method of preparing antibiotic complex
    FI112503B|2003-12-15|Polycyclic antiparasitic substances and their use
    SU648117A3|1979-02-15|Method of obtaining antibacterial substance
    JP3140228B2|2001-03-05|Novel macrocyclic lactone and its producing bacteria
    CA1208148A|1986-07-22|Cl-1577 antibiotic/antitumor compounds and theirproduction
    NL8001982A|1980-10-09|ANTIBIOTIC ACTIVE SUBSTANCE AND METHOD FOR PREPARING AND USING THIS SUBSTANCE AND PHARMACEUTICAL PREPARATION CONTAINING THIS SUBSTANCE.
    CA1153966A|1983-09-20|Physiologically active substance, ebelactone andproduction thereof
    SU999981A3|1983-02-23|Process for producing antibiotic complex having antitumoral effect
    EP0185456A2|1986-06-25|CL-1577D and CL-1577E antibiotic/antitumor compounds, their production and use
    LU85953A1|1986-01-24|ANTIBIOTIC ANTITUMOR COMPOUND
    SU751332A3|1980-07-23|Method of preparing a-35512 antibiotic complex
    SU882414A3|1981-11-15|Method of preparing c-15003 p-4 antibiotic
    GB2263112A|1993-07-14|New cyclic fr-900520 microbial biotransformation agent
    US3812249A|1974-05-21|Antibiotic bl580
    US3775255A|1973-11-27|L-trans-2-amino-4-|-3-butenoic acid
    US4360595A|1982-11-23|Fermentation process for producing anandimycin
    US3991183A|1976-11-09|Antibiotic produced by a species of micromonospora
    SU1296009A3|1987-03-07|Micromonospora sp.nrrl 15118 starin - producer of producer of antibiotic complex and method for producing antibiotic complex
    SU552907A3|1977-03-30|The method of obtaining antibiotics
    US3647776A|1972-03-07|1-hydroxy- and acetyloxy-3-|-2-butanone
    JP2004137175A|2004-05-13|New antibiotics, kigamicins, and their use
    SU741804A3|1980-06-15|Method of preparing antibiotic
    US5565561A|1996-10-15|Natural substance cyclamenol and chemical derivatives
    US4994271A|1991-02-19|BMY-40800 antitumor antibiotics
    US5087567A|1992-02-11|Antitumor antibiotic BMY-42428
    同族专利:
    公开号 | 公开日
    AU515853B2|1981-05-07|
    ZA772252B|1978-03-29|
    GB1555636A|1979-11-14|
    DK144978C|1982-12-06|
    FI55353B|1979-03-30|
    IE44818B1|1982-04-07|
    DK165077A|1977-10-16|
    HK53182A|1982-12-17|
    JPS6046960B2|1985-10-18|
    CH630957A5|1982-07-15|
    JPS52128365A|1977-10-27|
    FR2348224B1|1980-02-15|
    US4064014A|1977-12-20|
    SE7704194L|1977-10-16|
    BE853369A|1977-10-07|
    FI55353C|1979-07-10|
    SE435635B|1984-10-08|
    CY1161A|1983-01-28|
    KE3237A|1982-11-26|
    LU77114A1|1977-11-14|
    DE2716836C2|1985-08-14|
    FR2348224A1|1977-11-10|
    IE44818L|1977-10-15|
    US4039736A|1977-08-02|
    YU98777A|1982-06-30|
    GR73112B|1984-02-02|
    CA1091601A|1980-12-16|
    AU2382077A|1978-10-12|
    NL7704032A|1977-10-18|
    MY8400003A|1984-12-31|
    DK144978B|1982-07-19|
    DE2716836A1|1977-11-03|
    FI771142A|1977-10-16|
    YU39388B|1984-12-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1003383A|
    GB846130A|1956-03-23|1960-08-24|Ciba Ltd|New antibiotic and derivatives and salts thereof, preparations containing the same and process for the manufacture of these substances|
    US3092550A|1957-10-29|1963-06-04|Ciba Geigy Corp|Antibiotic danubomycin and process for its manufacture|
    CH362490A|1957-10-29|1962-06-15|Ciba Geigy|Process for the production of a new antibiotic|
    FR1533151A|1962-05-18|1968-07-19|Rhone Poulenc Sa|New antibiotic and its preparation|
    FR1527892A|1967-03-15|1968-06-07|Rhone Poulenc Sa|New process for preparing the antibiotic 13057 r.p.|
    YU33730B|1967-04-18|1978-02-28|Farmaceutici Italia|Process for preparing a novel antibiotic substance and salts thereof|
    US3803124A|1968-04-12|1974-04-09|Farmaceutici It Soc|Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives|
    US3686163A|1968-05-14|1972-08-22|Farmaceutici Italia|Dihydrodaunomycin antibiotic and derivatives thereof|
    FR1593235A|1968-11-18|1970-05-25|
    SU508076A1|1973-07-05|1976-10-05|Институт По Изысканию Новых Антибиотиков Амн Ссср|Method for preparing carminomycin 1|
    US3864480A|1974-05-06|1975-02-04|Merck & Co Inc|Cinerubin A and B As Antiparasitic Agents|
    JPS5134915B2|1974-07-27|1976-09-29|
    US4039736A|1976-04-15|1977-08-02|Bristol-Myers Company|Antibiotic compounds marcellomycin and musettamycin|US4039736A|1976-04-15|1977-08-02|Bristol-Myers Company|Antibiotic compounds marcellomycin and musettamycin|
    JPS5438103B2|1976-08-16|1979-11-19|
    US4209588A|1976-10-05|1980-06-24|Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai|Process for producing new antitumor anthracycline antibiotics|
    CH637160A5|1976-10-05|1983-07-15|Microbial Chem Res Found|PROCESS FOR THE MANUFACTURE OF ANTHRACYCLINE GLUCOSIDES.|
    US4123608A|1977-07-18|1978-10-31|Bristol-Myers Company|Antibiotic compound|
    NL7900869A|1978-02-09|1979-08-13|Erba Farmitalia|ANTHRACYCLINS ANTIBIOTICS.|
    JPS5543012A|1978-09-20|1980-03-26|Sanraku Inc|Novel anthracycline derivatine and its preparation|
    US4202967A|1978-10-02|1980-05-13|Sri International|N,N-pentamethylene derivatives of daunomycin and adriamycin|
    IT1196402B|1978-11-21|1988-11-16|Erba Farmitalia|ANTI-TUMORAL ANTIBIOTICS|
    JPS6023679B2|1979-07-13|1985-06-08|Sanraku Kk|
    CH648327A5|1980-10-16|1985-03-15|Hoffmann La Roche|ANTHRACYCLINE.|
    US5977082A|1985-08-02|1999-11-02|Pharmacia & Upjohn Company|Injectable ready-to-use solutions containing an antitumor anthracycline glycoside|
    US5124317A|1985-08-02|1992-06-23|Farmitalia Carlo Erba S.P.A.|Injectable ready-to-use solutions containing an antitumor anthracycline glycoside|
    US20050208037A1|2003-10-21|2005-09-22|Board Of Regents, The University Of Texas System|Thioredoxin increases redox-cycling of anticancer agents thereby sensitizes cancer cells to apoptosis|
    ES2381213T3|2006-02-14|2012-05-24|Henkel Ag & Co. Kgaa|Composition and manufacturing processes of a trivalent chromium coating, resistant to corrosion, drying "in situ", for application on metal surfaces|
    DE102008030910A1|2007-06-27|2009-01-02|Technische Universität Dresden|Apparatus and method for detecting a substance by particle plasmon resonanceor particle-mediated fluorescence based on cell surface polarizations|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/677,480|US4039736A|1976-04-15|1976-04-15|Antibiotic compounds marcellomycin and musettamycin|
    [返回顶部]